tavaborole
(LFQDNHWZDQTITF-UHFFFAOYSA-N)
Structure
- SMILES
- Fc1ccc2c(c1)COB2O
- Type(s)
- Approved; Investigational
- ATC code(s)
- D01AE24
- Molecular Formula:
- C7H6BFO2
- Molecular Weight:
- 151.931
- Log P:
- 0.0434
- Hydrogen Bond Acceptor:
- 2
- Hydrogen Bond Donor:
- 1
- TPSA:
- 29.46
- CAS Number(s):
- 174671-46-6
Synonym(s)
1.
tavaborole
2.
5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
3.
AN 2690
4.
AN-2690
5.
AN2690
6.
Kerydin
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Drug ineffective | FAERS: 86 | US FAERS | |
| 2 | Application site erythema | FAERS: 39 | SIDER US FAERS | |
| 3 | Application site exfoliation | FAERS: 34 | SIDER US FAERS | |
| 4 | Application site irritation | FAERS: 30 | US FAERS | |
| 5 | Application site pain | FAERS: 22 | US FAERS | |
| 6 | Drug administered at inappropriate site | FAERS: 21 | US FAERS | |
| 7 | Erythema | FAERS: 18 | US FAERS | |
| 8 | Pruritus | FAERS: 17 | US FAERS | |
| 9 | Accidental exposure to product | FAERS: 14 | US FAERS | |
| 10 | Hypersensitivity | FAERS: 13 | US FAERS | |
| 11 | Skin irritation | FAERS: 12 | SIDER US FAERS | |
| 12 | Burning sensation | FAERS: 11 | US FAERS | |
| 13 | Application site vesicles | FAERS: 10 | US FAERS | |
| 14 | Application site dryness | FAERS: 9 | US FAERS | |
| 15 | Application site inflammation | FAERS: 9 | US FAERS | |
| 16 | Dry skin | FAERS: 8 | US FAERS | |
| 17 | Malaise | FAERS: 8 | US FAERS | |
| 18 | Peripheral swelling | FAERS: 8 | US FAERS | |
| 19 | Drug effect incomplete | FAERS: 7 | US FAERS | |
| 20 | Onychoclasis | FAERS: 7 | US FAERS | |
| 21 | Onycholysis | FAERS: 6 | US FAERS | |
| 22 | Onychomycosis | FAERS: 6 | US FAERS | |
| 23 | Application site swelling | FAERS: 5 | US FAERS | |
| 24 | Inappropriate schedule of drug administration | FAERS: 5 | US FAERS | |
| 25 | Pain | FAERS: 5 | US FAERS | |
| 26 | Application site pruritus | FAERS: 4 | US FAERS | |
| 27 | Application site rash | FAERS: 4 | SIDER US FAERS | |
| 28 | Application site reaction | FAERS: 4 | US FAERS | |
| 29 | Drug dose omission | FAERS: 4 | US FAERS | |
| 30 | Laceration | FAERS: 4 | US FAERS | |
| 31 | Scab | FAERS: 4 | US FAERS | |
| 32 | Therapy cessation | FAERS: 4 | US FAERS | |
| 33 | Wrong technique in product usage process | FAERS: 4 | US FAERS | |
| 34 | Application site fissure | FAERS: 3 | US FAERS | |
| 35 | Dermatitis | FAERS: 3 | US FAERS | |
| 36 | Dysgeusia | FAERS: 3 | US FAERS | |
| 37 | Product use issue | FAERS: 3 | US FAERS | |
| 38 | Swelling | FAERS: 3 | US FAERS | |
| 39 | Application site infection | FAERS: 2 | US FAERS | |
| 40 | Application site warmth | FAERS: 2 | US FAERS | |
| 41 | Discomfort | FAERS: 2 | US FAERS | |
| 42 | Dizziness | FAERS: 2 | US FAERS | |
| 43 | Exposure via skin contact | FAERS: 2 | US FAERS | |
| 44 | Headache | FAERS: 2 | US FAERS | |
| 45 | Incorrect dose administered | FAERS: 2 | US FAERS | |
| 46 | Incorrect route of drug administration | FAERS: 2 | US FAERS | |
| 47 | Nasopharyngitis | FAERS: 2 | US FAERS | |
| 48 | Nausea | FAERS: 2 | US FAERS | |
| 49 | Onychomalacia | FAERS: 2 | US FAERS | |
| 50 | Overdose | FAERS: 2 | US FAERS | |
| 51 | Pain of skin | FAERS: 2 | US FAERS | |
| 52 | Palpitations | FAERS: 2 | US FAERS | |
| 53 | Poor quality product administered | FAERS: 2 | US FAERS | |
| 54 | Product dropper issue | FAERS: 2 | US FAERS | |
| 55 | Product leakage | FAERS: 2 | US FAERS | |
| 56 | Product physical issue | FAERS: 2 | US FAERS | |
| 57 | Product use complaint | FAERS: 2 | US FAERS | |
| 58 | Pyelonephritis | FAERS: 2 | US FAERS | |
| 59 | Urticaria | FAERS: 2 | US FAERS | |
| 60 | Abdominal Pain | FAERS: 1 | US FAERS | |
| 61 | Abdominal discomfort | FAERS: 1 | US FAERS | |
| 62 | Agitation | FAERS: 1 | US FAERS | |
| 63 | Alopecia | FAERS: 1 | US FAERS | |
| 64 | Amnesia | FAERS: 1 | US FAERS | |
| 65 | Anxiety | FAERS: 1 | US FAERS | |
| 66 | Application site discharge | FAERS: 1 | US FAERS | |
| 67 | Application site discomfort | FAERS: 1 | US FAERS | |
| 68 | Application site hypersensitivity | FAERS: 1 | US FAERS | |
| 69 | Application site papules | FAERS: 1 | US FAERS | |
| 70 | Arthralgia | FAERS: 1 | US FAERS | |
| 71 | Blood creatinine increased | FAERS: 1 | US FAERS | |
| 72 | Blood glucose increased | FAERS: 1 | US FAERS | |
| 73 | Blood sodium increased | FAERS: 1 | US FAERS | |
| 74 | Capillaritis | FAERS: 1 | US FAERS | |
| 75 | Cellulitis | FAERS: 1 | US FAERS | |
| 76 | Chest Pain | FAERS: 1 | US FAERS | |
| 77 | Chest discomfort | FAERS: 1 | US FAERS | |
| 78 | Device Failure | FAERS: 1 | US FAERS | |
| 79 | Drug administration error | FAERS: 1 | US FAERS | |
| 80 | Dyspepsia | FAERS: 1 | US FAERS | |
| 81 | Epistaxis | FAERS: 1 | US FAERS | |
| 82 | Exposure during breast feeding | FAERS: 1 | US FAERS | |
| 83 | Eye irritation | FAERS: 1 | US FAERS | |
| 84 | Fatigue | FAERS: 1 | US FAERS | |
| 85 | Feeling abnormal | FAERS: 1 | US FAERS | |
| 86 | Hyperacusis | FAERS: 1 | US FAERS | |
| 87 | Hyperkeratosis | FAERS: 1 | US FAERS | |
| 88 | Incorrect drug administration duration | FAERS: 1 | US FAERS | |
| 89 | Inflammation | FAERS: 1 | US FAERS | |
| 90 | Intentional product use issue | FAERS: 1 | US FAERS | |
| 91 | Intracranial Aneurysm | FAERS: 1 | US FAERS | |
| 92 | Joint swelling | FAERS: 1 | US FAERS | |
| 93 | Laryngitis | FAERS: 1 | US FAERS | |
| 94 | Limb discomfort | FAERS: 1 | US FAERS | |
| 95 | Macule | FAERS: 1 | US FAERS | |
| 96 | Medication Error | FAERS: 1 | US FAERS | |
| 97 | Medication residue present | FAERS: 1 | US FAERS | |
| 98 | Myocardial Infarction | FAERS: 1 | US FAERS | |
| 99 | Nail bed disorder | FAERS: 1 | US FAERS | |
| 100 | Nail discomfort | FAERS: 1 | US FAERS | |
| 101 | Nail necrosis | FAERS: 1 | US FAERS | |
| 102 | No adverse event | FAERS: 1 | US FAERS | |
| 103 | Onychalgia | FAERS: 1 | US FAERS | |
| 104 | Packaging design issue | FAERS: 1 | US FAERS | |
| 105 | Pancreatic carcinoma | FAERS: 1 | US FAERS | |
| 106 | Poor quality sleep | FAERS: 1 | US FAERS | |
| 107 | Pre-existing condition improved | FAERS: 1 | US FAERS | |
| 108 | Product packaging quantity issue | FAERS: 1 | US FAERS | |
| 109 | Pulmonary congestion | FAERS: 1 | US FAERS | |
| 110 | Purpura | FAERS: 1 | US FAERS | |
| 111 | Purulent discharge | FAERS: 1 | US FAERS | |
| 112 | Skin Erosion | FAERS: 1 | US FAERS | |
| 113 | Skin Ulcer | FAERS: 1 | US FAERS | |
| 114 | Stress | FAERS: 1 | US FAERS | |
| 115 | Symptom recurrence | FAERS: 1 | US FAERS | |
| 116 | Syncope | FAERS: 1 | US FAERS | |
| 117 | Therapeutic product effect incomplete | FAERS: 1 | US FAERS | |
| 118 | Therapeutic response unexpected | FAERS: 1 | US FAERS | |
| 119 | Tinea Pedis | FAERS: 1 | US FAERS | |
| 120 | Tinnitus | FAERS: 1 | US FAERS | |
| 121 | Unevaluable event | FAERS: 1 | US FAERS | |
| 122 | Vomiting | FAERS: 1 | US FAERS | |
| 123 | furuncle | FAERS: 1 | US FAERS |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.